Inventor · disambiguated record

Jing Wang

Also filed as: WANG JING · WANG JING YU

51 granted patents·58 pending applications·241 citations·filing 2005–2025

98Inventor score

Technology areasA61K C07D A61P C07K C12N

Files withARVINAS OPERATIONS INC62 ARVINAS INC17 TESARO INC5 INST OF BASIC MEDICAL SCIENCES CAMS4 INST OF BASIC MEDICAL SCIENCES OF CHINESE ACADEMY OF MEDICAL SCIENCES4

Top patents by PatentIndex Score

109 records

0198US11104666B2Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degradersARVINAS OPERATIONS INC·Filed 2020·Granted Aug 31, 2021·18 cites·15 claims
0298US10899742B1Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degradersARVINAS OPERATIONS INC·Filed 2020·Granted Jan 26, 2021·18 cites·25 claims
0398US10844021B2Compounds and methods for the targeted degradation of androgen receptorARVINAS OPERATIONS INC·Filed 2019·Granted Nov 24, 2020·13 cites·25 claims
0498US10647698B2Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degradersARVINAS INC·Filed 2017·Granted May 12, 2020·31 cites·6 claims
0598US10584101B2Compounds and methods for the targeted degradation of androgen receptorARVINAS INC·Filed 2017·Granted Mar 10, 2020·35 cites·6 claims
0697US11952347B2Compounds and methods for the targeted degradation of androgen receptorARVINAS OPERATIONS INC·Filed 2021·Granted Apr 9, 2024·3 cites·7 claims
0797US11597720B2Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degradersARVINAS OPERATIONS INC·Filed 2020·Granted Mar 7, 2023·4 cites·48 claims
0897US10730870B2Compounds and methods for the enhanced degradation of targeted proteinsARVINAS INC·Filed 2016·Granted Aug 4, 2020·25 cites·22 claims
0996US10772962B2Compounds and methods for the targeted degradation of bromodomain-containing proteinsARVINAS INC·Filed 2016·Granted Sep 15, 2020·15 cites·23 claims
1095US12053469B2Indazole based compounds and associated methods of useARVINAS OPERATIONS INC·Filed 2021·Granted Aug 6, 2024·6 cites·6 claims
1195US11981683B2Indazole based compounds and associated methods of useARVINAS OPERATIONS INC·Filed 2022·Granted May 14, 2024·5 cites·2 claims
1295US10723717B2Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptidesARVINAS INC·Filed 2017·Granted Jul 28, 2020·16 cites·44 claims
1392US11964945B2Compounds and methods for the targeted degradation of androgen receptorARVINAS OPERATIONS INC·Filed 2020·Granted Apr 23, 2024·2 cites·26 claims
1492US11173211B2Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptidesARVINAS OPERATIONS INC·Filed 2019·Granted Nov 16, 2021·6 cites·25 claims
1592US10071164B2Estrogen-related receptor alpha based protac compounds and associated methods of useUNIV YALE·Filed 2015·Granted Sep 11, 2018·8 cites·9 claims
1691US11384063B2Modulators of estrogen receptor proteolysis and associated methods of useARVINAS OPERATIONS INC·Filed 2020·Granted Jul 12, 2022·2 cites·8 claims
1790US11858940B2Selective modulators of mutant LRRK2 proteolysis and associated methods of useARVINAS OPERATIONS INC·Filed 2021·Granted Jan 2, 2024·2 cites·12 claims
1890US2025320195A1Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degradersARVINAS OPERATIONS INC·Filed 2024·Application pending·0 cites
1989US11191741B2Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptideARVINAS OPERATIONS INC·Filed 2017·Granted Dec 7, 2021·3 cites·13 claims
2089US11161841B2Modulators of proteolysis and associated methods of useARVINAS OPERATIONS INC·Filed 2019·Granted Nov 2, 2021·3 cites·22 claims
2189US2025034096A1Compounds and methods for the targeted degradation of androgen receptorARVINAS OPERATIONS INC·Filed 2024·Application pending·0 cites
2288US11352351B2Compounds and methods for the targeted degradation of androgen receptorARVINAS INC·Filed 2016·Granted Jun 7, 2022·4 cites·16 claims
2387US10604506B2Modulators of estrogen receptor proteolysis and associated methods of useARVINAS INC·Filed 2018·Granted Mar 31, 2020·3 cites·20 claims
2486US10994015B2EGFR proteolysis targeting chimeric molecules and associated methods of useARVINAS OPERATIONS INC·Filed 2017·Granted May 4, 2021·3 cites·25 claims
2585US12427144B2Compounds and methods for the targeted degradation of androgen receptorARVINAS OPERATIONS INC·Filed 2023·Granted Sep 30, 2025·0 cites·16 claims
2685US11427548B2Compounds and methods for the targeted degradation of androgen receptorARVINAS OPERATIONS INC·Filed 2019·Granted Aug 30, 2022·2 cites·15 claims
2785US2025228944A1Compounds and methods for the targeted degradation of bromodomain-containing proteinsARVINAS OPERATIONS INC·Filed 2024·Application pending·0 cites
2884US11661453B2Combination therapies for treating cancer with niraparib and PD-1 inhibitorsTESARO INC·Filed 2018·Granted May 30, 2023·3 cites·6 claims
2984US11512083B2Compounds and methods for the enhanced degradation of targeted proteinsARVINAS OPERATIONS INC·Filed 2020·Granted Nov 29, 2022·1 cites·17 claims
3084US2024076281A1Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degradersARVINAS OPERATIONS INC·Filed 2022·Application pending·0 cites
3182US11890281B2SHP2 phosphatase inhibitors and methods of making and using the sameRELAY THERAPEUTICS INC·Filed 2020·Granted Feb 6, 2024·1 cites·27 claims
3282US2025223265A1Compounds and methods for the targeted degradation of androgen receptorARVINAS OPERATIONS INC·Filed 2024·Application pending·0 cites
3381US11622961B2Combination therapies for treating cancerTESARO INC·Filed 2018·Granted Apr 11, 2023·2 cites·10 claims
3481US10865202B2Indole derivatives as estrogen receptor degradersARVINAS OPERATIONS INC·Filed 2019·Granted Dec 15, 2020·1 cites·20 claims
3580US12171831B2Compounds and methods for the targeted degradation of bromodomain- containing proteinsARVINAS OPERATIONS INC·Filed 2022·Granted Dec 24, 2024·0 cites·14 claims
3679US12441708B2Cereblon ligands and bifunctional compounds comprising the sameARVINAS OPERATIONS INC·Filed 2022·Granted Oct 14, 2025·0 cites·20 claims
3779US12239711B2Cereblon ligands and bifunctional compounds comprising the sameARVINAS OPERATIONS INC·Filed 2022·Granted Mar 4, 2025·0 cites·1 claims
3879US2024382599A1Egfr proteolysis targeting chimeric molecules and associated methods of useARVINAS OPERATIONS INC·Filed 2024·Application pending·0 cites
3978US12264157B2Compounds and methods for the enhanced degradation of targeted proteinsARVINAS OPERATIONS INC·Filed 2022·Granted Apr 1, 2025·0 cites·24 claims
4078US12172981B2Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degradersARVINAS OPERATIONS INC·Filed 2021·Granted Dec 24, 2024·0 cites·18 claims
4178US2025313547A1Cereblon ligands and bifunctional compounds comprising the sameARVINAS OPERATIONS INC·Filed 2025·Application pending·0 cites
4277US2025360219A1Cereblon ligands and bifunctional compounds comprising the sameARVINAS OPERATIONS INC·Filed 2025·Application pending·0 cites
4376US2024059686A1Compounds and methods for the targeted degradation of the androgen receptorARVINAS OPERATIONS INC·Filed 2022·Application pending·0 cites
4474US11926665B2Methods of treating cancer with anti-TIM-3 antibodiesTESARO INC·Filed 2018·Granted Mar 12, 2024·2 cites·13 claims
4574US2024299366A1Imide-based modulators of proteolysis and associated methods of useARVINAS OPERATIONS INC·Filed 2023·Application pending·0 cites
4674US2025114356A1Indazole based compounds and associated methods of useARVINAS OPERATIONS INC·Filed 2024·Application pending·0 cites
4774US2025236612A1Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of useARVINAS OPERATIONS INC·Filed 2024·Application pending·0 cites
4874US2021040044A1Compounds and methods for the targeted degradation of androgen receptorARVINAS OPERATIONS INC·Filed 2020·Application pending·0 cites
4973US12473294B2Selective modulators of mutant LRRK2 proteolysis and associated methods of useARVINAS OPERATIONS INC·Filed 2023·Granted Nov 18, 2025·0 cites·11 claims
5073US12275716B2Modulators of estrogen receptor proteolysis and associated methods of useARVINAS OPERATIONS INC·Filed 2022·Granted Apr 15, 2025·0 cites·16 claims

Showing the top 50 of 109 patent records by PatentIndex Score.

Join the waitlist — get patent alerts

Get an alert when Jing Wang files or is granted a new patent.

We store only your email — no account needed. See our privacy policy.

Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →